Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Another 2,300 AstraZeneca jobs go but 'simplification will lead to growth', says Soriot

This article was originally published in Scrip

Executive Summary

AstraZeneca has outlined its strategic plans under new CEO Pascal Soriot ahead of an investor briefing in New York later today (March 21). AstraZeneca's newly stated strategic priorities include restructuring its SG&A activities with resultant significant job losses, driving its on-market growth platforms in a bid to return to growth, and achieving "scientific leadership". On the latter front, the firm announced a $240 million upfront discovery alliance with small biotech company Moderna Therapeutics, which is focused on mRNAi.


Related Content


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts